F-1/A: Polyrizon Ltd. Files for IPO to Advance Nasal Spray Medical Device Technology

Polyrizon Ltd. is seeking to go public to fund the development of its nasal spray medical devices designed to block viruses and allergens.

Summary

• Polyrizon Ltd., a development stage biotech company, has filed an amendment to its Form F-1 registration statement for an initial public offering (IPO).
• The company is offering up to 807,692 units, each consisting of one ordinary share and three warrants, with an anticipated IPO price between $4.38 and $6.02 per unit.
• Polyrizon is also offering up to 807,692 pre-funded units, each consisting of one pre-funded warrant and three warrants, for investors who cannot exceed a certain ownership threshold.
• The company intends to list its ordinary shares on the Nasdaq Capital Market under the symbol PLRZ.
• Polyrizon is developing nasal spray hydrogels using its Capture and Contain (C&C) technology to block viruses and allergens, and its Trap and Target (T&T) technology for nasal drug delivery.
• Key product candidates include PL-14 (nasal allergy blocker), PL-15 (COVID-19 blocker), and PL-16 (influenza blocker).
• The company expects PL-14 to be regulated as a Class II medical device under the 510(k) pathway, while PL-15 and PL-16 are expected to be regulated as Class II medical devices under a De Novo Classification request.
• Polyrizon has entered into an exclusive patent license agreement with SciSparc for its SCI-160 platform to develop pain treatments.
• The company also has a collaboration agreement with NurExone Biologic Inc. to develop an intranasal delivery system for spinal cord injuries.
• Polyrizon anticipates using approximately $450,000 of the IPO proceeds to complete preclinical development for PL-14, PL-15, and PL-16, $600,000 to complete clinical development for PL-14, $300,000 to complete in vitro feasibility studies for T&T platform technology product candidates, and $310,000 to repay convertible loans.
• The remainder of the proceeds will be used for working capital, general corporate purposes, and possible future acquisitions.
• The company has incurred significant losses since its inception and expects to continue incurring losses for the foreseeable future.

Sentiment

Score: 5

Explanation: The document presents a mix of positive and negative aspects. The company is developing innovative technology and targeting large markets, but it also faces significant financial challenges and regulatory hurdles. The sentiment is neutral overall.

Positives

• The company's products target large and growing markets, including allergic rhinitis, nasal viral infections, and pain management.
• Polyrizon has a collaboration agreement with NurExone Biologic Inc. to develop an intranasal delivery system for spinal cord injuries.
• The company's management team has extensive experience in the life sciences industry.
• The company has a Scientific Advisory Board of professors with expertise in drug delivery systems, chemistry and pharmaceuticals.

Negatives

• The company has incurred significant losses since its inception and expects to continue incurring losses for the foreseeable future.
• The company has never generated any revenue from product candidates sales and may never be profitable.
• The company will need to raise substantial additional funding, which may not be available on acceptable terms, or at all.
• The company is heavily dependent on the success of its C&C product candidates.
• The company has not previously conducted pivotal clinical trials.
• The company's headquarters and other significant operations are located in Israel, and, therefore, its results may be adversely affected by political, economic and military instability in Israel, including the recent attack by Hamas and other terrorist organizations from the Gaza Strip and Israels war against them.

Risks

• The company's business is subject to a number of risks, including financial condition, capital requirements, product candidate development, clinical testing, reliance on third parties, intellectual property, business operations, commercialization, and regulatory issues.
• The company depends on enrollment of patients in its upcoming clinical trials in order to continue development of its product candidates.
• The company may not receive, or may be delayed in receiving, the necessary clearances or approvals for its product candidates.
• The company does not plan to conduct a pre-submission meeting with the FDAs CDRH to confirm the potential for the Class II medical device path under a de novo classification request for its PL-15 and PL-16 products until after the completion of this initial public offering.
• The company is heavily dependent on the success of its C&C product candidates.
• The company's headquarters and other significant operations are located in Israel, and, therefore, its results may be adversely affected by political, economic and military instability in Israel, including the recent attack by Hamas and other terrorist organizations from the Gaza Strip and Israels war against them.

Future Outlook

The company expects its expenses and operating losses to increase for the foreseeable future as it continues clinical development of its C&C product candidates and develops other product candidates using its T&T platform technology.

Industry Context

The document notes that the medical device and pharmaceutical industry is intensely competitive and subject to rapid and significant technological change. The company is aware of various existing therapies in the market and in development that may in the future compete with its product candidates.

Comparison to Industry Standards

• The FDA submission and clearance process for Alzair, Nasalese, and Bentrio, predicate devices for Polyrizon's PL-14 product candidate, took 86 and 140 days, respectively.
• The global cold and cough remedies market is valued at $42.65 billion in 2024 and is expected to grow at a CAGR of 6.18% from 2024 to 2029.
• The global therapeutic market for allergic rhinitis is projected to reach $16 billion by 2032, growing at a CAGR of 2.5% from 2023 to 2032.
• The global allergen blocker market will reach $214.5 million in 2030, growing at a CAGR of 3.64% during 2023-2030.
• The global market for intranasal drug delivery is projected to reach $136.46 billion by 2032, growing at a CAGR of 7.18%.
• The INCS products market is estimated to reach $11.2 billion by 2033.
• The benzodiazepines drug market is expected to reach $4.2 billion by 2032, which reflects a CAGR of 3.7% during 2024-2032.
• The market for Benzodiazepines for seizure clusters is estimated to be around $700 million.
• The global naloxone market is expected to grow to $2.47 billion in 2032, at a CAGR of 11% between 2023 and 2032.
• The naloxone intranasal spray market is projected to attain a value of $1.4 billion by 2030.
• The global pain management drugs market size was estimated at $78.14 billion in 2022 and is projected to hit around $115 billion by 2032, growing at a CAGR of 3.94% during the forecast period 2023 to 2032.

Related Party Transactions

• On February 4, 2023, we entered into a convertible loan agreement with Reuven Srugo Construction Company Ltd., or Reuven Construction and XYLO, pursuant to which Reuven Construction and XYLO extended a loan the Company in the principal amount of $180,000, with an annual interest rate of approximately 4%.
• In June 2023, December 2023 and May 2024, we entered into a series of securities purchase agreements with certain of our principal shareholders, including XYLO, Raul Srugo, Itzhak Srugo, Yoav Srugo and Sofi Yochelman Srugo, pursuant to which we issued an aggregate of 513,878 Ordinary Shares for gross proceeds of $582,000.

Stakeholder Impact

• Shareholders: Potential dilution from the issuance of new shares and warrants.
• Employees: Potential for increased job opportunities and career advancement as the company grows.
• Customers: Potential for new and innovative products to address unmet needs in the healthcare market.
• Suppliers: Potential for increased business opportunities as the company expands its operations.
• Creditors: Repayment of convertible loans with IPO proceeds.

Next Steps

• Initiate preclinical safety trials for PL-14, PL-15, and PL-16 in Q2 2025.
• Commence pivotal clinical trial on PL-14 in Q4 2025.
• Submit a 510(k) application for PL-14 to the FDA.
• Submit a Q-submission (Pre-submission) for PL-15 and PL-16 to the FDA.
• Schedule a pre-submission meeting with the FDA's CDRH to confirm the potential for the Class II medical device path under a de novo classification request for PL-15 and PL-16.
• Initiate feasibility clinical trials for PL-16 in Q1 2026.
• Initiate pivotal clinical trials for PL-16 in Q3 2026.
• Initiate feasibility clinical trials for PL-15 in Q3 2026.
• Initiate pivotal clinical trials for PL-15 in Q2 2027.
• Submit De Novo Classification requests for PL-15 and PL-16 to the FDA.
• Conduct feasibility studies for T&T platform product candidates with corticosteroids, benzodiazepines, and naloxone, beginning in Q4 2024 through Q1 2026.
• Begin pre-clinical studies for the T&T platform product candidates in Q2 2026.
• Plan Phase I clinical trials for the leading T&T technology product candidate for Q4 2027.
• Start initial testing to explore the potential of the SCI-160 platform when combined with the T&T technology, in Q1 2025.

Key Dates

Keywords

Polyrizon, IPO, nasal spray, medical device, Capture and Contain, Trap and Target, PL-14, PL-15, PL-16, SciSparc, NurExone, hydrogel, allergies, COVID-19, influenza